---
title: "4D-150 in Neovascular age-related macular degeneration: References"
description: "Reference list for the formulary evidence report on 4D-150 in Neovascular age-related macular degeneration. 181 cited documents."
canonical: "https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/references"
published: "2026-09-17T18:33:01-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# 4D-150 in Neovascular age-related macular degeneration: References

<a id="references"></a>

## 5 References

1. [4D Molecular Therapeutics 2026 company update (2026)](https://www.globenewswire.com/news-release/2026/01/07/3214461/0/en/4DMT-Provides-Company-Update-and-Anticipated-Development-Milestones-for-2026.html)
2. [4D Molecular Therapeutics 4FRONT-1 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/02/09/3234480/0/en/4DMT-Completes-Enrollment-for-4FRONT-1-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)
3. [4D Molecular Therapeutics 4FRONT-1 first patients announcement (2025)](https://www.globenewswire.com/news-release/2025/03/10/3039669/0/en/4DMT-Announces-First-Patients-Enrolled-in-4FRONT-1-Phase-3-Clinical-Trial-Evaluating-4D-150-in-Wet-AMD.html)
4. [4D Molecular Therapeutics 4FRONT-2 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4DMT-Completes-Enrollment-for-4FRONT-2-Global-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)
5. [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)
6. [4D Molecular Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm)
7. [4D Molecular Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349173/fdmt-20260630.htm)
8. [4D Molecular Therapeutics Form 8-K PRISM 2-year data (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/d98747d8k.htm)
9. [4D Molecular Therapeutics Form 8-K protocol amendment (2025)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm)
10. [4D Molecular Therapeutics Otsuka license announcement (2025)](https://www.globenewswire.com/news-release/2025/10/31/3178071/0/en/4DMT-Announces-Exclusive-License-Agreement-with-Otsuka-Pharmaceutical-Co-Ltd-for-Development-and-Commercialization-of-4D-150-in-Asia-Pacific.html)
11. [4D Molecular Therapeutics Phase 3 acceleration announcement (2025)](https://www.globenewswire.com/news-release/2025/07/02/3109526/0/en/4DMT-Announces-Accelerated-4D-150-Phase-3-Development-in-Wet-AMD-and-Streamlined-Organization-to-Drive-Late-Stage-Execution.html)
12. [4D Molecular Therapeutics PRIME designation announcement (2023)](https://www.globenewswire.com/news-release/2023/10/23/2764682/0/en/4DMT-Receives-EMA-Priority-Medicines-PRIME-Designation-for-4D-150-Clinical-Stage-Genetic-Medicine-for-Treatment-of-Wet-AMD.html)
13. [4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/04/27/2656152/0/en/4DMT-Presents-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ARVO-2023.html)
14. [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html)
15. [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html)
16. [4D Molecular Therapeutics PRISM injection-free subgroup analyses announcement (2024)](https://www.globenewswire.com/news-release/2024/06/08/2895689/0/en/4DMT-Presents-Injection-Free-Subgroup-Analyses-from-4D-150-Phase-2-PRISM-Randomized-Dose-Expansion-Cohort-in-Wet-AMD-Patients-with-Severe-Disease-Activity-High-Treatment-Burden-at-.html)
17. [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)
18. [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html)
19. [4D Molecular Therapeutics PRISM Phase 2b 52-week results announcement (2025)](https://www.globenewswire.com/news-release/2025/02/08/3023106/0/en/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-long-term-durability-data-supporting-4d-150-4front-global-registration-program.html)
20. [4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html)
21. [4D Molecular Therapeutics RMAT designation announcement (2023)](https://www.globenewswire.com/news-release/2023/12/21/2799961/0/en/4DMT-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-4D-150-Genetic-Medicine-for-Intravitreal-Treatment-of-Wet-AMD-the-First-RMAT-Designation-in-Wet-AMD.html)
22. [4D Molecular Therapeutics second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm)
23. [4D Molecular Therapeutics third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526458477/fdmt-20260930.htm)
24. [4D Molecular Therapeutics third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526458394/fdmt-ex99_1.htm)
25. [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and)
26. [Abu Al-Burak et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41812994/)
27. [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)
28. [Amoaku et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4469673/)
29. [Anastasopoulos et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17157603/)
30. [ARVO Annual Meeting (2023)](https://iovs.arvojournals.org/article.aspx?articleid=2789669)
31. [ARVO Annual Meeting (2025)](https://iovs.arvojournals.org/article.aspx?articleid=2804417)
32. [Asanad et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41934654/)
33. [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf)
34. [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)
35. [Baljoon et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13194801/)
36. [Baumal et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32344075/)
37. [Berkowitz and Patel (2021)](https://pubmed.ncbi.nlm.nih.gov/32818623/)
38. [Bhisitkul et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25640411/)
39. [Bloch et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22264944/)
40. [Bowen et al. (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ASGCT2026_BowenA_Abstract2206.pdf)
41. [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/)
42. [Brown et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17021319/)
43. [Brown et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26428606/)
44. [Brown et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32565050/)
45. [Brown et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37981235/)
46. [Brown et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39182627/)
47. [Bryan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12592112/)
48. [Busbee et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23352196/)
49. [Calton et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11614000/)
50. [Campochiaro et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39209113/)
51. [CATT Research Group (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3157322/)
52. [Centers for Medicare & Medicaid Services Quality ID 14 (2019)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2019_Measure_014_MIPSCQM.pdf)
53. [Chakravarthy et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3009619/)
54. [Chakravarthy et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23870813/)
55. [Cheung et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42586317/)
56. [Christakis et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7246151/)
57. [Ciulla et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31324588/)
58. [ClinicalTrials.gov NCT04704921](https://clinicaltrials.gov/study/NCT04704921)
59. [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)
60. [ClinicalTrials.gov NCT05407636](https://clinicaltrials.gov/study/NCT05407636)
61. [ClinicalTrials.gov NCT06223958](https://clinicaltrials.gov/study/NCT06223958)
62. [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)
63. [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)
64. [ClinicalTrials.gov NCT06856577](https://clinicaltrials.gov/study/NCT06856577)
65. [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)
66. [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)
67. [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/july-2026-medicare-part-b-payment-limit-files.zip)
68. [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/76a714ad-3a2c-43ac-b76d-9dadf8f7d890/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J0177&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J0178&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J0179&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2777&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2778&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2779&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Q5124&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Q5128&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Q5147)
69. [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J0177&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J0178&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Q5147&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2777&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2778&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2779&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Q5124&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=Q5128&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J0179)
70. [Comparison of Age-related Macular Degeneration Treatments Trials Research Group (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4958614/)
71. [DailyMed BEOVU prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d)
72. [DailyMed EYLEA HD label (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86d8848b-111b-4da9-8957-7cccef1b8f66)
73. [DailyMed EYLEA prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96cfd69-da34-41ee-90a9-610a4655cd1c)
74. [DailyMed LUCENTIS prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d)
75. [DailyMed SUSVIMO label (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c6d9e2a-9a77-4d11-b692-de87cfde3444)
76. [DailyMed VABYSMO label (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04cc9ef7-c02a-4e92-a655-0062674e8487)
77. [DailyMed VISUDYNE prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=952f4c80-50b1-4308-9ee6-311ffefb13df)
78. [Dang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11211988/)
79. [Daniel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6015772/)
80. [Danzig (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_Clinical-Trials-at-the-Summit_Danzig_PRISM-24-week-Results_vFinal_6June2024.pdf)
81. [Dawson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4094542/)
82. [Desai et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38315793/)
83. [Dickson and James (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10492178/)
84. [Dugel et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/30986442/)
85. [Dugel et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32574761/)
86. [Eichenbaum (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_Retina-Society_Eichenbaum_PRISM-Phase-2-Interim-Results_vF.pdf)
87. [Eichenbaum et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39154860/)
88. [EU Clinical Trials Information System 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public/view/2025-521349-25-00)
89. [EU CTIS 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-521349-25-00)
90. [Eye Diseases Prevalence Research Group (2004)](https://pubmed.ncbi.nlm.nih.gov/15078675/)
91. [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)
92. [FDA Non-Inferiority Clinical Trials to Establish Effectiveness guidance (2016)](https://www.fda.gov/media/78504/download)
93. [Finger et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7368708/)
94. [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)
95. [Franco et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42479493/)
96. [Gale et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10084380/)
97. [Gale et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41861959/)
98. [GBD 2019 Blindness and Vision Impairment Collaborators (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7820391/)
99. [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)
100. [Gillies et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31606444/)
101. [Gohil et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4461306/)
102. [Grunwald et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5234734/)
103. [Heier et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23084240/)
104. [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)
105. [Ho et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33231696/)
106. [Hoffmann-La Roche TENAYA protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/87/NCT03823287/Prot_000.pdf)
107. [Holekamp et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24388973/)
108. [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/)
109. [Holz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4316940/)
110. [Investing.com Morgan Stanley Global Healthcare Conference transcript (2026)](https://www.investing.com/news/transcripts/4d-molecular-therapeutics-at-morgan-stanley-conference-gene-therapy-push-93CH-4900651)
111. [Jabbarpoor Bonyadi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29423786/)
112. [Javitt et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12917168/)
113. [Johnson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6646972/)
114. [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf)
115. [Kertes et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6990694/)
116. [Khanani (2024a)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis_PRISM-Phase-2-Initial-Results.pdf)
117. [Khanani (2024d)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_EURETINA-2024_PRISM_Presentation_9_17_2459.pdf)
118. [Khanani et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8613703/)
119. [Khanani et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/4D-150_ARVO-2023-Presentation_FINAL.pdf)
120. [Khanani et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38382813/)
121. [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)
122. [Kim et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13473015/)
123. [Kodiak Sciences DAYLIGHT statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04964089/SAP_001.pdf)
124. [Koh et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710379/)
125. [Korobelnik et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40876598/)
126. [Kuznik et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12534633/)
127. [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)
128. [Leitch et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178757/)
129. [Li et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712255/)
130. [Maesa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9291450/)
131. [Malhotra et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798985/)
132. [Managed Healthcare Executive (2025)](https://www.managedhealthcareexecutive.com/view/step-therapy-associated-with-more-switching-of-anti-vegf-treatment-study-finds-asrs-2025)
133. [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)
134. [McGuinness et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28139151/)
135. [Mitchell et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30303083/)
136. [National Institute for Health and Care Excellence (2018)](https://www.nice.org.uk/guidance/ng82/chapter/Recommendations)
137. [Niazi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31654492/)
138. [Obeid et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583857/)
139. [Ocular Therapeutix SOL-1 topline results announcement (2026)](https://www.globenewswire.com/news-release/2026/02/17/3239086/0/en/ocular-therapeutix-reports-positive-results-from-landmark-sol-1-phase-3-superiority-trial-in-wet-amd.html)
140. [Okada et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403101/)
141. [Patel (2018)](https://pubmed.ncbi.nlm.nih.gov/31047530/)
142. [Pieramici (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis-2025-PRISM-Ph2b-Dante_08-Feb-2025_vFF-1.pdf)
143. [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)
144. [Quesada et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40293479/)
145. [Regillo et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26231305/)
146. [Rein et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34560128/)
147. [Rein et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)
148. [Repka and Woodke (2025)](https://www.aao.org/eyenet/article/92137-octa-66683-iris-prosthesis)
149. [Rofagha et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23642856/)
150. [Rosenfeld et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17021318/)
151. [Rosenfeld et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29655642/)
152. [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)
153. [Sadda et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32081493/)
154. [Schmidt-Erfurth et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4145443/)
155. [Senra et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28302534/)
156. [Silva (2024)](https://www.retinalphysician.com/issues/2024/october/the-evolution-of-clinical-trial-endpoints-for-wet-amd/)
157. [Singh and Sørensen (2012)](https://pubmed.ncbi.nlm.nih.gov/21106047/)
158. [Sood et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9204613/)
159. [Spaide et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559632/)
160. [Spark Therapeutics Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm)
161. [Spark Therapeutics Form 8-K (2018)](https://www.sec.gov/Archives/edgar/data/1609351/000119312518001117/d519914d8k.htm)
162. [Spooner et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41223128/)
163. [Stein et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3632297/)
164. [Teo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13250100/)
165. [Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group (1999)](https://pubmed.ncbi.nlm.nih.gov/10532441/)
166. [Tsang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10870181/)
167. [Van Vu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11156866/)
168. [Varano et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4671808/)
169. [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)
170. [Viola et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39208778/)
171. [Vision Loss Expert Group of the Global Burden of Disease Study (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11269688/)
172. [Vu et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32981226/)
173. [Vu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10482823/)
174. [WHO Collaborating Centre for Drug Statistics Methodology ATC index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=S01LA&showdescription=yes)
175. [Willmington et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12922378/)
176. [Windsor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5732022/)
177. [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)
178. [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)
179. [Wykoff et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28779006/)
180. [Xin et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28665868/)
181. [Zhang et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37116720/)

## Related pages
- [4D-150: Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration.md)
- [4D-150 in Neovascular age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/terms-and-abbreviations.md)
- [4D-150: Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/executive-summary.md)
- [4D-150 in Neovascular age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/product-information-and-disease-description.md)
- [4D-150 in Neovascular age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/clinical-evidence.md)
- [4D-150 in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/economics.md)
- [4D-150 in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/prevalence.md)
- [4D-150 in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
